Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Contact Dermatitis Update

Description

In this session on contact dermatitis, Bill James, an emeritus professor from the University of Pennsylvania, provides a comprehensive update on the latest allergens and trends in the field. The presentation highlights the emergence of sulfites as the contact allergen of the year, noting their increasing prevalence in food, medications, and personal care products. MI (methylisothiazolinone), previously less prominent, is now the second most common allergen, showing significant impacts due to regulatory changes in Canada and the EU. Advances in technology for patch testing, especially for patients on immunosuppressive treatments, and demographic trends in allergy prevalence are also covered. Specific patient groups, such as children and those from underrepresented communities, are noted for varying sensitivities to allergens like hair dye and lanolin. James emphasizes the importance of thorough evaluation and patch testing for recurrent dermatitis cases and addressing patients with negative test results by educating them about possible unknown allergens. Overall, he advocates for continued vigilance in managing contact dermatitis and adapting practices based on emerging evidence.

View more

Conclusions

  • Sulfites have emerged as a significant allergen, particularly in foods and personal care products, with a notable prevalence in patch-tested patients.
  • Methylisothiazolinone (MI) has risen dramatically in allergy reports, now ranking as the second most common allergen in the US.
  • Regulatory actions in Canada and the European Union have successfully reduced the prevalence of allergens like nickel and chrome.
  • Patch testing remains an effective diagnostic tool but may miss certain allergens, particularly fragrance and rubber additives.
  • Certain demographic groups, such as women using nail cosmetics, are more prone to specific allergies like acrylates and MI.
  • The presentation highlighted the importance of proper patient education and management strategies for those with negative patch tests.
  • Innovations in technology may enhance the patch testing process and monitoring of patients with suspected allergic reactions.
  • Dermatitis 2024; 35: 6
  • Dermatitis 2013; 24: 2
  • JAMA Dermatol 2023; 159; 267
  • Dermatitis 2023; 34: 90
  • Br J Dermatol 2023: Dec 7
  • JAAD 2024; 90: 319
  • Acta Pediatr 2020; 109: 2692
  • JAAD 2023; 89: 808
  • Contact Dermatitis 2023; 89: 401
  • Contact Dermatitis 2023; 88: 326
  • Dermatitis 2023; 34: 475
  • Cutis 2022; 110: 175
  • Dermatitis 2022; 33: 193
  • Dermatitis 2023; Jan 2
  • Dermatitis 2023; 34: 550
  • Dermatitis 2023; 34: 449
  • Vaccines (Basel) 2022; 11: 1906
  • Practical Derm 2018; 109: 485
  • Contact Dermatitis 1999; 41: 18
  • JAAD 2019; 80: 1618